In vitro and in vivo activity of HER2-targeted antibody-liposomal doxorubicin conjugate MM-302 in HER2-intermediate tumors

被引：0
|
作者：
Geretti, E.
Espelin, C.
Adiwijaya, B.
Coma, S.
Koncki, Z.
Sumner, P.
Dumont, N.
Garcia, G.
Bloom, T.
Janovsky, J.
Reynolds, J.
Campbell, K.
Moyo, V.
Molnar, I.
LoRusso, P.
Krop, I.
Miller, K.
Ma, C.
Munster, P.
Wickham, T.
机构：
[1] Merrimack Pharmaceut Inc, Cambridge, MA USA
[2] Yale Canc Ctr, New Haven, CT USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA
[5] Washington Univ, Sch Med, St Louis, MO USA
[6] Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.SABCS16-P4-21-40
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4-21-40
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Development of a competitive ELISA for the quantification of F5 conjugate in HER2-targeted STEALTH immunoliposome doxorubicin in plasma samples
    Ran Hu
    Rebecca Davis
    Yongjin Yao
    Yaodong Xu
    Analytical and Bioanalytical Chemistry, 2006, 386 : 1657 - 1664
  • [42] In vitro functional analysis of HER2 variants in lung cancers to evaluate their oncogenic activity and predict response to HER2-targeted therapy.
    Liu, Dazhi
    Offin, Michael David
    Olah, Zachary T.
    Tarcic, Gabi
    Zelichov, Ori
    Vidne, Michael
    Drilon, Alexander E.
    Arcila, Maria E.
    Li, Bob T.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [43] HER2-targeted recombinant protein immuno-caspase-6 effectively induces apoptosis in HER2-overexpressing GBM cells in vitro and in vivo
    Zhang, Leiming
    Ren, Junlin
    Zhang, Hangyu
    Cheng, Gang
    Xu, Yanming
    Yang, Shuangwu
    Dong, Chao
    Fang, Dandong
    Zhang, Jianning
    Yang, Angang
    ONCOLOGY REPORTS, 2016, 36 (05) : 2689 - 2696
  • [44] The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody-drug conjugate-resistant HER2-overexpressing breast cancer
    Lee, Jangsoon
    Kida, Kumiko
    Koh, Jiwon
    Liu, Huey
    Manyam, Ganiraju C.
    Gi, Young Jin
    Rampa, Dileep R.
    Multani, Asha S.
    Wang, Jing
    Jayachandran, Gitanjali
    Lee, Dae-Won
    Reuben, James M.
    Sahin, Aysegul
    Huo, Lei
    Tripathy, Debu
    Im, Seock-Ah
    Ueno, Naoto T.
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2024, 43 (01)
  • [45] Optimization of lead antibody selection for XMT-1522, a novel, highly potent HER2-targeted antibody-drug conjugate (ADC)
    Bodyak, Natasha
    Yurkovetskiy, Alex
    Gumerov, Dmitry R.
    Xiao, Dongmei
    Thomas, Joshua D. Thomad D.
    Poling, Laura L.
    Qin, LiuLiang
    Yin, Mao
    DeVit, Michael J.
    Park, Peter U.
    Lee, Winnie
    Prinz, Bianka
    Bergstrom, Donald A.
    Lowinger, Timothy B.
    CANCER RESEARCH, 2016, 76
  • [46] Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2
    Mutlu, Levent
    McNamara, Blair
    Bellone, Stefania
    Manavella, Diego D.
    Demirkiran, Cem
    Greenman, Michelle
    Verzosa, Miguel Skyler Z.
    Buza, Natalia
    Hui, Pei
    Hartwich, Tobias Max Philipp
    Harold, Justin
    Yang-Hartwich, Yang
    Zipponi, Margherita
    Altwerger, Gary
    Ratner, Elena
    Huang, Gloria S.
    Clark, Mitchell
    Andikyan, Vaagn
    Azodi, Masoud
    Schwartz, Peter E.
    Santin, Alessandro D.
    CLINICAL & EXPERIMENTAL METASTASIS, 2024, : 765 - 775
  • [47] Safety, anti-tumour activity, and biomarker results of the HER2-targeted bispecific antibody ZW25 in HER2-expressing solid tumours
    Meric-Bernstam, F.
    Hanna, D.
    Beeram, M.
    Lee, K. -W.
    Kang, Y. -K.
    Chaves, J.
    Lee, J.
    Goodwin, R.
    Vaklavas, C.
    Oh, D. -Y.
    Rha, S. Y.
    Elimova, E.
    Mayordomo, J.
    Ferrario, C.
    Cobleigh, M. A.
    Fortenberry, A.
    Rowse, G.
    Gray, T.
    Lai, R.
    Hamilton, E.
    ANNALS OF ONCOLOGY, 2019, 30 : 167 - +
  • [48] Safety, anti-tumour activity, and biomarker results of the HER2-targeted bispecific antibody ZW25 in HER2-expressing solid tumours
    Oh, D-Y.
    Hamilton, E.
    Hanna, D.
    Beeram, M.
    Lee, K-W.
    Kang, Y-K.
    Chaves, J.
    Lee, J-Y.
    Goodwin, R.
    Vaklavas, C.
    Rha, S-Y.
    Elimova, E.
    Mayordomo, J.
    Ferrario, C.
    Cobleigh, M.
    Fortenberry, A.
    Rowse, G.
    Gray, T.
    Lai, R.
    Bernstam, F. Meric
    ANNALS OF ONCOLOGY, 2019, 30
  • [49] Impact of Tumor HER2/ERBB2 Expression Level on HER2-Targeted Liposomal Doxorubicin-Mediated Drug Delivery: Multiple Low-Affinity Interactions Lead to a Threshold Effect
    Hendriks, Bart S.
    Klinz, Stephan G.
    Reynolds, Joseph G.
    Espelin, Christopher W.
    Gaddy, Daniel F.
    Wickham, Thomas J.
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (09) : 1816 - 1828
  • [50] Clinical Implications of Pathophysiological and Demographic Covariates on the Population Pharmacokinetics of Trastuzumab Emtansine, a HER2-Targeted Antibody-Drug Conjugate, in Patients With HER2-Positive Metastatic Breast Cancer
    Gupta, Manish
    LoRusso, Patricia M.
    Wang, Bei
    Yi, Joo-Hee
    Burris, Howard A., III
    Beeram, Muralidhar
    Modi, Shanu
    Chu, Yu-Waye
    Agresta, Samuel
    Klencke, Barbara
    Joshi, Amita
    Girish, Sandhya
    JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 52 (05): : 691 - 703
12345